HYLORIS PHARMACEUTICALS SA (HYL.BR) Stock Balance Sheet
EBR:HYL - Euronext Brussels - BE0974363955 - Common Stock - Currency: EUR
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 23.59M | 30.20M | 43.46M | 50.01M | 64.40M | |||
| Marketable Securities | 556.00K | 499.00K | 10.47M | 528.00K | 7.00K | |||
| Receivables | 5.37M | 3.81M | 4.13M | 2.32M | 253.00K | |||
| Other Current Assets | 191.00K | 1.19M | 3.50M | 1.10M | 1.95M | |||
| Total Current Assets | 29.71M | 35.31M | 49.80M | 53.96M | 66.61M | |||
| Non-Current Assets | ||||||||
| PPE Net | 1.99M | 2.15M | 1.06M | 295.00K | 176.00K | |||
| Investments And Advances | 3.75M | 4.80M | 4.95M | 4.53M | 12.00K | |||
| Intangibles | 3.84M | 3.83M | 3.61M | 2.94M | 2.38M | |||
| Other Non-Current Assets | N/A | 1.59M | 1.31M | 1.71M | N/A | |||
| Total Non-Current Assets | 11.63M | 12.37M | 10.93M | 9.48M | 2.57M | |||
| TOTAL ASSETS | 41.34M | 47.68M | 60.73M | 63.44M | 69.18M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 326.00K | 241.00K | 138.00K | 65.00K | 46.00K | |||
| Accounts Payable | 3.43M | 3.32M | 2.42M | 2.75M | 1.63M | |||
| Other Current Liabilities | 3.41M | 3.20M | 3.21M | 12.16M | 457.00K | |||
| Total Current Liabilities | 7.16M | 6.76M | 5.77M | 14.98M | 2.13M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 1.86M | 1.85M | 1.05M | 109.00K | 106.00K | |||
| Other Non-Current Liabilities | 173.00K | -1.00K | 300.00K | 301.00K | 7.88M | |||
| Total Non-Current Liabilities | 2.03M | 1.85M | 1.05M | 410.00K | 7.99M | |||
| TOTAL LIABILITIES | 9.19M | 8.61M | 6.82M | 15.39M | 10.12M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -85.05M | -78.12M | -63.28M | -55.77M | -44.76M | |||
| Additional Paid In Capital | 121.51M | 121.51M | 121.51M | 103.69M | 103.69M | |||
| Minority Interest | N/A | N/A | N/A | N/A | N/A | |||
| Common Shares | 140.00K | 140.00K | 140.00K | 129.00K | 129.00K | |||
| Other Shareholders' Equity | -4.46M | -4.46M | -4.46M | -1.00K | N/A | |||
| Shares Outstanding | 28.00M | 28.00M | 28.00M | 25.83M | 25.59M | |||
| Tangible Book Value per Share | 1.01 | 1.26 | 1.80 | 1.75 | 2.21 | |||
| Total Shareholders' Equity | 32.14M | 39.07M | 53.91M | 48.06M | 59.06M | |||
| TOTAL LIABILITIES AND EQUITY | 41.34M | 47.68M | 60.73M | 63.44M | 69.18M | |||
| Statistics | ||||||||
| Debt/Equity | 0.06 | 0.05 | 0.02 | 0.00 | 0.00 | |||
| Current Ratio | 4.15 | 5.22 | 8.63 | 3.60 | 31.24 | |||
| Return On Assets (ROA) | -15.34% | -32.26% | -19.61% | -18.25% | -10.33% | |||
| Return On Equity (ROE) | -19.73% | -39.37% | -22.09% | -24.09% | -12.10% | |||
All data in EUR , ROIC based on taxRate of 0.25